Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 17/20 | 0.54 |
| ▸ | KDM5B | Q9UGL1 | 16/20 | 0.54 |
| ▸ | KDM4C | Q9H3R0 | 14/20 | 0.54 |
| ▸ | KDM2B | Q8NHM5 | 3/20 | 0.44 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
| ▸ | KDM4A | O75164 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1767416 | 0.81 | SCD (0.56) | — | |
| SCHEMBL1767517 | 0.81 | SCD (0.57) | KDM5AKDM5BKDM4C | |
| SCHEMBL1767396 | 0.79 | SCD (0.45) | KDM5AKDM5B | |
| SCHEMBL1569155 | 0.77 | KDM5A (0.58) | KDM5AKDM5BKDM4CKDM2BPPARD | |
| SCHEMBL1767551 | 0.75 | SCD (0.53) | — | |
| SCHEMBL1767431 | 0.71 | SCD (0.67) | — | |
| SCHEMBL15778478 | 0.70 | KDM5A (1.00) | KDM5AKDM5BKDM4CKDM2B | |
| SCHEMBL1767411 | 0.70 | SCD (0.52) | — | |
| SCHEMBL1767465 | 0.69 | SCD (0.53) | — | |
| SCHEMBL348307 | 0.69 | SCD (0.80) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160289191-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2016-10-06 | — | — | US | disclosed |
| US-9187426-B2 | Organic compounds | NOVARTIS AG (CH) | 2015-11-17 | — | — | US | disclosed |
| US-20110105530-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105530-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | KDM5A 797/4885KDM5B 779/4885KDM4C 533/4885 |
| US-20160289191-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | KDM5A 797/4885KDM5B 779/4885KDM4C 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.